THALES
30.3.2021 09:02:06 CEST | Business Wire | Press release
Thales today announced that it has been named as a Market Leader in the 2021 KuppingerCole Leadership Compass for Database and Big Data Security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005025/en/
The report recognised Thales’ leadership role within the data security market through its CipherTrust Data Security Platform . Thales’ flagship data security platform was praised for its data discovery and classification, transparent encryption, and database and application data protection. The report also commended CipherTrust’s data masking, tokenization, access controls, enterprise key management, and cloud key management functions.
“The CipherTrust Data Security Platform now provides a full range of data-centric security capabilities, including data discovery and classification, transparent encryption, database and application data protection, data masking, tokenization, access controls, enterprise key management, and cloud key management unified from a single management interface. Its unified, ubiquitous approach across all available IT environments enables multiple business-focused use cases beyond just compliance, including reduction of data security complexity, accelerating cloud migrations, and reducing data exposure risks significantly across whole enterprises,” said Alexi Balaganski, Lead Analyst at KuppingerCole.
With the accelerated move to the cloud and decentralisation of business operations due to the COVID-19 pandemic, effective data security has become even more essential for safeguarding businesses against cybercrime. The Thales 2020 Data Threat Report reveals that 100% of businesses surveyed report that at least some of the sensitive data they are storing in the cloud is not encrypted. According to the report, only 54% of sensitive data in the cloud is protected by encryption and even less (44%) is protected by tokenisation. Despite this, a fifth of firms (20%) intend to reduce data security spend in the next year. A centralized data security platform, that protects data across all of an organization’s environments, can save an organization time and money while improving security compliance.
“Covid-19 has changed the way that we use, store, and access data. Hackers are looking for potential vulnerabilities to access this sensitive data in remote databases and big data arrays. Our CipherTrust Data Security Platform provides powerful and easy to use tools to discover, protect and control their data no matter where it resides.” said Todd Moore, Vice President of Encryption Solutions at Thales . “It’s hugely rewarding to be noted by KuppingerCole as a leader in database and big data security. This recognition illustrates Thales’s strong offering within the market and our continued commitment to meet our customers’ ever more complex data privacy needs.”
CipherTrust Data Security Platform is in a single platform dedicated to simplifying the data security compliance process that combines both Thales’s Vormetric and SafeNet KeySecure technologies. It was developed to unify data discovery, classification, and risk-analysis functions with encryption, access, data masking and key management to provide seamless and comprehensive protection from breaches.
Download the full KuppingerCole Report Leadership Compass for Database and Big Data Security .
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Security
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005025/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom